Author + information
To assess the clinical effects and safety of Nesiritide in the treatment of patients with acute decompensated heart failure (ADHF).
126 patients with ADHF who received Nesiritide treatment in CCU department of nanfang hospital from March 2014 to May 2015 were analyzed. All patients were treated with Nesiritide in addition to routine heart failure therapy. Clinical effects were evaluated mainly according to the clinical symptoms before treatment, 24 h after treatment and before discharged, including the changes of respiratory rate (RR), heart rate (HR), New York Heart Association functional class (NYHA), N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular end-diastolic diameter (LV), left ventricular ejection fraction (LVEF) and troponin-I (Tn-I).
108(85.7%) patients were significantly improved in cardiac function, while 8 patients were not obviously improved in cardiac function, 4 patients died of heart failure, 4 patients died of infection aggravation and 2 of them died of sudden malignant arrhythmias. After 24 h treatment with Nesiritide, RR and HR were improved significantly (P<0.05), the grade of NYHA was also improved (P<0.05) and NT-proBNP reduced greatly (P<0.05). Furthermore, before discharged, patients' RR, HR, NYHA, NT-proBNP were further improved (P<0.05), LV reduced (P<0.05), LVEF increased significantly (P<0.05), TnI decreased significantly, and the average inpatient day dropped to 9.3±6.1 (1∼28) days.
RR, HR, LV, LVEF, NT-proBNP and NYHA classification of the patients with ADHF can be effectively improved by the routine therapy in combination with Nesiritide. Furthermore, there was no visible negative influence on the systolic blood pressure, liver and kidney functions.